LMAT - LeMaitre Vascular Inc Stock Price, Fair Value and News

78.49USD+0.81 (+1.04%)Market Closed

Market Summary

USD78.49+0.81

Market Closed

1.04%

LMAT Alerts

2 major insider sales recently.

Big jump in Earnings (Y/Y)

LMAT Stock Price

View Fullscreen

LMAT RSI Chart

LMAT Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

51.89

Price/Sales (Trailing)

8.81

EV/EBITDA

32.25

Price/Free Cashflow

44.55

LMAT Price/Sales (Trailing)

LMAT Profitability

EBT Margin

22.14%

Return on Equity

11.01%

Return on Assets

9.59%

Free Cashflow Yield

2.24%

LMAT Fundamentals

LMAT Revenue

Revenue (TTM)

199.9M

Rev. Growth (Yr)

13.6%

Rev. Growth (Qtr)

9.4%

LMAT Earnings

Earnings (TTM)

34.0M

Earnings Growth (Yr)

63.69%

Earnings Growth (Qtr)

16.8%

Breaking Down LMAT Revenue

Last 7 days

3.1%

Last 30 days

24.5%

Last 90 days

25.5%

Trailing 12 Months

24.3%

How does LMAT drawdown profile look like?

LMAT Financial Health

Current Ratio

7.57

LMAT Investor Care

Dividend Yield

0.74%

Dividend/Share (TTM)

0.58

Shares Dilution (1Y)

1.31%

Diluted EPS (TTM)

1.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	199.9M	0	0	0
2023	169.2M	177.2M	185.6M	193.5M
2022	158.1M	159.5M	160.2M	161.7M
2021	134.7M	150.5M	152.5M	154.4M
2020	119.3M	114.7M	122.0M	129.4M
2019	108.1M	110.5M	115.5M	117.2M
2018	102.7M	104.0M	103.3M	105.6M
2017	92.1M	95.1M	98.0M	100.9M
2016	79.7M	82.2M	86.3M	87.7M
2015	73.3M	75.0M	76.5M	78.4M
2014	65.9M	68.1M	70.3M	71.1M
2013	58.2M	59.8M	61.4M	64.5M
2012	57.0M	56.3M	55.3M	56.7M
2011	56.8M	57.8M	58.7M	57.7M
2010	0	52.6M	54.3M	56.1M
2009	0	0	0	50.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of LeMaitre Vascular Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	lemaitre george w	sold	-602,427	75.3034	-8,000	chairman and ceo
May 07, 2024	lemaitre george w	sold	-3,496,060	75.5089	-46,300	chairman and ceo
May 06, 2024	lemaitre george w	sold	-5,216,010	75.6975	-68,906	chairman and ceo
May 06, 2024	roberts david b	sold	-379,990	75.62	-5,025	president and director
Mar 22, 2024	lemaitre george w	acquired	709,693	47.9263	14,808	chairman and ceo
Mar 08, 2024	kamke trent g	sold	-309,684	68.1824	-4,542	senior v. p., operations
Mar 07, 2024	roush john a	sold	-517,500	69.00	-7,500	-
Mar 05, 2024	jasinski lawrence j	sold	-344,925	67.5	-5,110	-
Mar 04, 2024	lemaitre george w	sold	-2,489,740	68.0258	-36,600	chairman and ceo
Mar 01, 2024	lemaitre george w	sold	-2,511,880	67.8539	-37,019	chairman and ceo

Which funds bought or sold LMAT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Grandeur Peak Global Advisors, LLC	sold off	-100	-187,592	-	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-25.61	-125,041	834,544	-%
May 16, 2024	Beacon Capital Management, LLC	new	-	1,858	1,858	-%
May 16, 2024	COMERICA BANK	reduced	-3.71	1,149,400	10,288,500	0.04%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.19	129,897	1,327,930	-%
May 16, 2024	AWM Investment Company, Inc.	reduced	-10.00	681,720	13,736,500	1.80%
May 15, 2024	MERCER GLOBAL ADVISORS INC /ADV	new	-	206,000	206,000	-%
May 15, 2024	Ranger Investment Management, L.P.	reduced	-9.73	2,867,920	54,661,600	3.52%
May 15, 2024	Squarepoint Ops LLC	reduced	-33.56	-717,928	2,497,920	-%
May 15, 2024	Quarry LP	new	-	1,128	1,128	-%

Are Funds Buying or Selling LMAT?

Are funds buying LMAT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LMAT

No. of Funds

Unveiling LeMaitre Vascular Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	6.96%	1,548,870	SC 13G/A
Feb 12, 2024	lemaitre george w	10.3%	2,283,204	SC 13G/A
Jan 22, 2024	copeland capital management, llc	5.7%	1,259,961	SC 13G
Jan 22, 2024	blackrock inc.	14.8%	3,296,788	SC 13G/A
Jan 05, 2024	conestoga capital advisors, llc	9.26%	2,061,262	SC 13G/A
Feb 09, 2023	vanguard group inc	6.72%	1,477,542	SC 13G/A
Jan 31, 2023	lemaitre george w	11.5%	2,532,694	SC 13G/A
Jan 26, 2023	blackrock inc.	14.9%	3,284,565	SC 13G/A
Jan 20, 2023	blackrock inc.	14.9%	3,284,565	SC 13G
Jan 18, 2023	conestoga capital advisors, llc	8.81%	1,938,886	SC 13G/A

Recent SEC filings of LeMaitre Vascular Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	144	Notice of Insider Sale Intent
May 15, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 10, 2024	10-Q	Quarterly Report
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 06, 2024	144	Notice of Insider Sale Intent
May 06, 2024	144	Notice of Insider Sale Intent
May 06, 2024	144	Notice of Insider Sale Intent
May 02, 2024	8-K	Current Report

Peers (Alternatives to LeMaitre Vascular Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

LeMaitre Vascular Inc News

Latest updates

LeMaitre Vascular Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	9.4%	53.00	49.00	47.00	50.00	47.00	41.00	39.00	42.00	40.00	40.00	38.00	41.00	36.00	38.00	36.00	25.00	31.00	30.00	29.00	29.00	28.00
Gross Profit	10.2%	37.00	33.00	31.00	32.00	31.00	26.00	25.00	28.00	26.00	26.00	25.00	27.00	24.00	24.00	23.00	17.00	20.00	20.00	20.00	20.00	19.00
Operating Expenses	7.5%	25.00	23.00	22.00	23.00	23.00	19.00	19.00	22.00	18.00	18.00	16.00	16.00	16.00	15.00	13.00	12.00	16.00	15.00	14.00	14.00	15.00
S&GA Expenses	13.8%	12.00	10.00	10.00	10.00	11.00	9.00	8.00	8.00	8.00	7.00	7.00	7.00	6.00	6.00	5.00	5.00	8.00	7.00	7.00	8.00	8.00
R&D Expenses	-6.0%	4.00	4.00	4.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	3.00	2.00	2.00	2.00	2.00
EBITDA Margin	6.3%	0.27*	0.25*	0.24*	0.23*	0.22*	0.23*	0.24*	0.26*	0.30*	0.31*	0.32*	0.33*	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	1.00	1.00	0.00	1.00	1.00	1.00	0.00	-	-	-	-	-
Income Taxes	2.2%	3.00	3.00	2.00	2.00	2.00	2.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
Earnings Before Taxes	13.1%	13.00	11.00	10.00	10.00	8.00	8.00	6.00	6.00	8.00	8.00	8.00	10.00	7.00	9.00	9.00	5.00	4.00	5.00	6.00	6.00	5.00
EBT Margin	8.5%	0.22*	0.20*	0.19*	0.18*	0.16*	0.17*	0.17*	0.19*	0.22*	0.22*	0.23*	0.24*	-	-	-	-	-	-	-	-	-
Net Income	16.8%	10.00	8.00	8.00	8.00	6.00	6.00	5.00	4.00	6.00	6.00	7.00	8.00	6.00	7.00	8.00	4.00	3.00	5.00	5.00	5.00	4.00
Net Income Margin	9.2%	0.17*	0.16*	0.15*	0.14*	0.12*	0.13*	0.13*	0.14*	0.17*	0.17*	0.18*	0.19*	-	-	-	-	-	-	-	-	-
Free Cashflow	-52.8%	5.00	11.00	11.00	11.00	2.00	3.00	7.00	9.00	4.00	4.00	13.00	9.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	2.1%	354	347	334	326	315	310	302	299	292	293	289	247	247	253	262	256	185	188	170	163	160
Current Assets	4.3%	203	195	182	174	165	162	153	148	141	140	134	90.00	91.00	94.00	102	92.00	90.00	92.00	100	98.00	95.00
Cash Equivalents	9.6%	27.00	24.00	18.00	19.00	17.00	19.00	17.00	21.00	16.00	14.00	17.00	22.00	24.00	27.00	29.00	20.00	11.00	12.00	12.00	13.00	15.00
Net PPE	1.9%	22.00	22.00	21.00	21.00	19.00	18.00	15.00	16.00	17.00	17.00	17.00	16.00	15.00	15.00	14.00	16.00	15.00	15.00	14.00	14.00	14.00
Goodwill	0%	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	27.00	40.00	40.00	6.00	3.00	30.00
Liabilities	-7.0%	45.00	49.00	45.00	43.00	41.00	42.00	41.00	41.00	35.00	39.00	40.00	61.00	70.00	80.00	101	103	36.00	40.00	28.00	25.00	27.00
Current Liabilities	-10.3%	27.00	30.00	29.00	26.00	24.00	25.00	23.00	23.00	18.00	22.00	22.00	21.00	22.00	25.00	44.00	44.00	17.00	21.00	19.00	17.00	19.00
Shareholder's Equity	3.6%	309	298	289	284	274	268	261	258	258	254	249	186	178	173	161	153	149	148	142	138	133
Retained Earnings	5.5%	122	115	110	106	101	98.00	95.00	92.00	91.00	88.00	84.00	80.00	74.00	71.00	65.00	60.00	58.00	57.00	54.00	51.00	48.00
Additional Paid-In Capital	2.8%	206	201	198	197	192	189	187	185	183	182	179	119	117	115	110	108	107	106	104	101	100
Shares Outstanding	0.7%	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	21.00	22.00	21.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,300	-	-	-	879	-	-	-	729	-	-	-	289	-	-	-	262	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-52.8%	5,071	10,746	11,823	11,903	2,279	4,077	7,342	9,248	4,711	5,056	14,075	9,897	6,074	14,152	14,112	5,347	1,189	5,594	4,470	4,334	-219
Share Based Compensation	14.7%	1,610	1,404	1,313	1,312	1,290	684	1,186	1,136	1,167	886	797	869	927	753	687	803	779	547	655	694	746
Cashflow From Investing	-4.4%	-2,361	-2,261	-9,851	-9,639	-2,964	-402	-8,460	-973	-536	-7,246	-51,368	-1,402	-1,060	3,673	1,347	-57,886	-25.00	-3,546	-5,728	-3,070	-11,756
Cashflow From Financing	101.5%	39.00	-2,686	-3,122	502	-1,825	-2,122	-2,147	-2,585	-2,380	-1,159	33,365	-10,539	-7,965	-21,005	-6,474	61,375	-1,741	-2,220	16.00	-2,842	424
Dividend Payments	15.2%	3,589	3,116	3,117	3,116	3,099	2,750	2,750	2,745	2,743	2,406	2,401	2,267	2,262	1,936	1,925	1,917	1,917	1,701	1,691	-	-
Buy Backs	-46.3%	358	667	5.00	9.00	172	490	3.00	4.00	145	428	286	-	88.00	279	234	-	57.00	237	423	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LMAT Income Statement

2024-03-31

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net sales	$ 53,478	$ 47,075
Cost of sales	16,813	16,192
Gross profit	36,665	30,883
Sales and marketing	11,686	10,897
General and administrative	9,013	7,932
Research and development	4,092	3,875
Restructuring	0	305
Total operating expenses	24,791	23,009
Income from operations	11,874	7,874
Other income (expense):
Interest income	1,001	568
Foreign currency loss	(78)	(425)
Income before income taxes	12,797	8,017
Provision for income taxes	2,910	1,977
Net income	$ 9,887	$ 6,040
Earnings per share of common stock:
Basic (in dollars per share)	$ 0.44	$ 0.27
Diluted (in dollars per share)	$ 0.44	$ 0.27
Weighted-average shares outstanding:
Basic (in shares)	22,365	22,111
Diluted (in shares)	22,570	22,274
Cash dividends declared per common share (in dollars per share)	$ 0.16	$ 0.14

LMAT Balance Sheet

2024-03-31

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 26,595	$ 24,269
Short-term marketable securities	81,693	80,805
Accounts receivable, net of allowances of $1,285 at March 31, 2024 and $941 at December 31, 2023	30,236	25,064
Inventory and other deferred costs	60,575	58,080
Prepaid expenses and other current assets	3,863	6,380
Total current assets	202,962	194,598
Property and equipment, net	22,174	21,754
Right-of-use leased assets	17,795	18,027
Goodwill	65,945	65,945
Other intangibles, net	40,239	41,711
Deferred tax assets	828	1,003
Other assets	4,014	3,740
Total assets	353,957	346,778
Current liabilities:
Accounts payable	3,089	3,734
Accrued expenses	21,118	23,650
Acquisition-related obligations	75	24
Lease liabilities - short-term	2,528	2,471
Total current liabilities	26,810	29,879
Lease liabilities - long-term	16,354	16,624
Deferred tax liabilities	114	107
Other long-term liabilities	2,176	2,268
Total liabilities	45,454	48,878
Stockholders’ equity:
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding	0	0
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 24,036,300 shares at March 31, 2024, and 23,911,760 shares at December 31, 2023	240	239
Additional paid-in capital	206,350	200,755
Retained earnings	121,728	115,430
Accumulated other comprehensive loss	(5,558)	(4,625)
Treasury stock, at cost; 1,590,362 shares at March 31, 2024 and 1,584,512 shares at December 31, 2023	(14,257)	(13,899)
Total stockholders’ equity	308,503	297,900
Total liabilities and stockholders’ equity	$ 353,957	$ 346,778

About LeMaitre Vascular Inc

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

CEO	Mr. George W. LeMaitre
WEBSITE	lemaitre.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	591

LeMaitre Vascular Inc Frequently Asked Questions

What is the ticker symbol for LeMaitre Vascular Inc? What does LMAT stand for in stocks?

LMAT is the stock ticker symbol of LeMaitre Vascular Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of LeMaitre Vascular Inc (LMAT)?

As of Fri May 17 2024, market cap of LeMaitre Vascular Inc is 1.76 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LMAT stock?

You can check LMAT's fair value in chart for subscribers.

What is the fair value of LMAT stock?

You can check LMAT's fair value in chart for subscribers. The fair value of LeMaitre Vascular Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of LeMaitre Vascular Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LMAT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is LeMaitre Vascular Inc a good stock to buy?

The fair value guage provides a quick view whether LMAT is over valued or under valued. Whether LeMaitre Vascular Inc is cheap or expensive depends on the assumptions which impact LeMaitre Vascular Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LMAT.

What is LeMaitre Vascular Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LMAT's PE ratio (Price to Earnings) is 51.89 and Price to Sales (PS) ratio is 8.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LMAT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on LeMaitre Vascular Inc's stock?

In the past 10 years, LeMaitre Vascular Inc has provided 0.27 (multiply by 100 for percentage) rate of return.